Neil Schluger, MD, is Professor of Epidemiology and Environmental Health Sciences and Professor of Medicine at the College of Physicians and Surgeons at the Columbia University Medical Center (CUMC). Dr. Schluger is interim chair of the Department of Epidemiology at Columbia's Mailman School of Public Health and Chief of the Division of Pulmonary, Allergy and Critical Care Medicine at CUMC. Dr. Schluger's academic and public health careers have focused on global aspects of lung disease, with a particular focus on tuberculosis. He began his career working at Bellevue Hospital at the height of New York City's tuberculosis epidemic in the early 1990s, and worked closely with the New York City Department of Health to craft a public health response to the epidemic. After moving to Columbia and joining the faculty at the Mailman School of Public Health and the College of Physicians and Surgeons, he published a landmark epidemiology study examining the dynamics of tuberculosis transmission in New York City that was published in the New England Journal of Medicine. He is currently engaged in epidemiology studies examining risks for drug-susceptible and drug-resistant tuberculosis in Kazakhstan with colleagues at Mailman and Columbia's Global Health Research Center for Central Asia. He developed and has taught a course at Mailman entitled Epidemiology and Control of Tuberculosis for the past 12 years, has supervised many masters students, and chaired or served on several PhD committees for epidemiology students. Dr. Schluger is the author of over 150 articles, chapters and books, and his work has been published in The New England Journal of Medicine, JAMA, The Lancet, The Lancet Respiratory Medicine and the American Journal of Respiratory and Critical Care Medicine, among other leading journals. He serves on the editorial boards of The American Journal of Respiratory and Critical Medicine, the Annals of the American Thoracic Society, and Chest. Dr. Schluger is a past-president of the American Lung Association of New York, and he has served as an advisor to the Bill and Melinda Gates Foundation. He also currently serves as the Chairman of the Steering Committee of the Tuberculosis Trials Consortium (TBTC), an international research consortium funded by the U.S. Centers for Disease Control and Prevention. He serves as the Chief Scientific Officer for World Lung Foundation (WLF) and is the founder and director of the East Africa Training Initiative, a WLF-sponsored project to train pulmonary physicians in Ethiopia. Under this initiative, expert faculty are in residence in Addis Ababa to train Ethiopian physicians in clinical and public health aspects of lung health. This program is the first of its kind in East Africa, and will create capacity and expertise in lung disease in Ethiopia and neighboring countries.
Honors & Awards
Areas of Expertise
Select Urban Health Activities
Tuberculosis Trials Consortium: The Tuberculosis Trials Consortium (TBTC) is an international research consortium funded by the Centers for Disease Control and Prevention (CDC) that conducts clinical trials aimed at developing new treatments for active tuberculosis and latent tuberculosis infection. Dr. Schluger is the principal investigator for the consortium's Columbia University site, which is run in conjunction with the New York City Department of Health Tuberculosis Control Program and enrolls patients through several of the Department of Health Chest Clinics.
Geng E, Kreiswirth B, Burzynski J, Schluger NW Clinical and radiographic correlates of primary and reactivation tuberculosis: a molecular epidemiologic study JAMA 293 2740-5 2005
Tuberculosis Trials Consortium Rifapentine and isoniazid once a week versus rifampicin and isoniazid twice a week for treatment of drug-susceptible pulmonary tuberculosis in HIV-negative patients: a randomised clinical trial Lancet 360 528-534 2002
Geng E, Kreiswirth B, Driver C, Li J, Burzynski J, Della Latta P, LaPaz A, Schluger NW Changes in tuberculosis transmission in New York City from 1990-1999: implications for tuberculosis control and elimination practices. New England Journal of Medicine 346 1453-1458 2002
Schluger NW, Perez D, Liu YM Reconstitution of immune responses to tuberculosis in HIV-infected patients receiving anti-retroviral therapy Chest 122 597-602 2002
Schluger NW Challenges of treating latent tuberculosis infection Chest 121 1733-1735 2002
Rom WN, Saray SM Tuberculosis Lippincott Williams and Wilkins Philadelphia 663-688 2003
Rom WN, Garay SM Tuberculosis Lippincott Williams and Wilkins Philadelphia 177-184 2003
Schluger NW, Burzynski J Tuberculosis in HIV-infected patients: epidemiology, pathogenesis, treatment HIV Clinical Trials 2 356-365 2001
The Tuberculosis Trials Consortium The Tuberculosis Trials Consortium: a model for clinical trials Collaborations Public Health Reports 116 (Supplement 1) 41-49 2001
Condos R, Hull FP, Schluger NW, Rom WN, Smaldone GC Regional deposition of aerosolized interferon-gamma in pulmonary tuberculosis Chest 125 2146-2155 2004
Schluger, NW Assessing Tuberculosis Transmission and Virulence: The Vanishing Tuberculin Skin Test Am J Respir Crit Care Med 2006 173 942 2006